6.5 C
New York
Monday, July 26, 2021

The rising cost of medicines is not only due to the difficulty in developing them

Must Read

Kuldeep Singh
Kuldeep is a Journalist and Writer at Revyuh.com. He writes about topics such as Apps, how to, tips and tricks, social network and covers the latest story from the ground. He stands in front of and behind the camera, creates creative product images and much more. Always ready to review new products. Email: kuldeep (at) revyuh (dot) com

The price of many medications is so high, and increasingly, that this may put public health systems at risk. In addition, the current system discourages research into necessary but unprofitable medicines.

It is often argued that the high cost of medicines is mainly, due to how difficult it is to develop them. However, things are not so simple.

Opacity

The cost of R&D of a new medicine exceeds $ 2.5 billion (about 2,130 million euros), a process that lasts between 12 and 14 years. However, the cost of developing a specific medicine is usually opaque and difficult to verify, as suggested by a study published in JAMA Internal Medicine.

The study analyzed anticancer drugs, and it was observed that the development cost of the molecules studied was below half of the calculations usually presented by the pharmaceutical industry. Not to mention that the benefits obtained in the first years after the commercialization of these medicines already made the medicine profitable.

As Javier Padilla abounds in his book, whom are we going to let die?:

In this regard, recently, WHO has approved an initiative to improve transparency in the drug research process, although they eventually lowered initial expectations regarding the standardization and detailed publication of drug research costs.

In addition to all this, there is a kind of public-private parasitization, in which private companies take advantage of research in the public sphere to patent and exploit medicines under a monopoly regime:

(…) the public initiative was present in a fundamental and indispensable way in the development of subsequently very expensive and cost-effective medicines (sofosbuvir, infliximab, abiraterone) without implying the introduction of public interest criteria in pricing and in its commercialization so as to ensure that the knowledge generated with public funds would translate into a greater facility for access to these medicines by the population that needed them.

These issues will have to be taken into account when addressing what comes to us: the progressive ageing of the population and the chronicity of diseases in more developed societies are opening the way to a scenario of growth in health spending in the Medium and long term.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest News

Covid Vaccine: Who will need a third dose

A major decision is expected from the US Centers for Disease Control and Prevention regarding a possible third dose...
- Advertisement -

More Articles Like This

- Advertisement -